ライフサイエンスコーパス: gastrin-releasing peptide

1 ducing vasoactive intestinal polypeptide and gastrin-releasing peptide.

2 ombesin-like peptides neuromedin B (NMB) and gastrin-releasing peptide.

3 transient receptor potential subtype V1 and gastrin-releasing peptide.

4 -containing SCN cells are immunopositive for gastrin-releasing peptide.

5 re localized to the SCN subregion containing gastrin-releasing peptide.

6 nes stably transfected with the receptor for gastrin releasing peptide, a physiologic stimulant of NT

7 g neurons respond to histamine and coexpress gastrin-releasing peptide, a peptide involved in itch se

8 of the mitogenic neuropeptide receptors for gastrin-releasing peptide and arginine vasopressin.

9 ed release of the pruritogenic neuropeptides gastrin-releasing peptide and atrial natriuretic peptide

10 Gastrin cells respond to both gastrin-releasing peptide and carbachol but not to chole

11 lease of the itch and analgesia transmitters gastrin-releasing peptide and leucine-enkephalin.

12 ropeptides of the bombesin family, including gastrin-releasing peptide and neuromedin B, which are fo

13 r, although two low affinity antagonists for gastrin-releasing peptide and NMB receptors, [D-Arg1,D-T

14 Gastrin-releasing peptide and other bombesin-like peptid

15 ranscription that regulate these parameters: gastrin-releasing peptide and the small conductance, cal

16 gastrin, chromogranin A and normal levels of gastrin-releasing peptide, and 9 other hormones.

17 opressin, vasoactive intestinal polypeptide, gastrin-releasing peptide, and corticotropin-releasing f

18 on of ASH1, the neuroendocrine growth factor gastrin-releasing peptide, and neuroendocrine markers sy

19 uitary adenylate cyclase-activating peptide, gastrin-releasing peptide, and substance P is reviewed.

20 , via activation of antral neurons secreting gastrin-releasing peptide, and that the antral innervati

21 ve agonist stimulated scratching behavior by gastrin-releasing peptide- and opioid-dependent mechanis

22 A gastrin-releasing peptide antagonist inhibited the post-

23 We identified the Grp gene, encoding gastrin-releasing peptide, as being highly expressed bot

24 3], which binds to the cell surface bombesin/gastrin-releasing peptide (BBN/GRP) receptor, was conjug

25 tagonists, JV-1-65 and JV-1-63, and bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC-3940-II

26 Antagonists of bombesin/gastrin-releasing peptide (BN/GRP) have been developed t

27 cers, treatment with antagonists of bombesin/gastrin-releasing peptide (BN/GRP) produces a reduction

28 rian cancer, or therapeutic utility, such as gastrin-releasing peptide/bombesin in lung carcinomas.

29 ts, blocking calcium mobilization induced by gastrin-releasing peptide, bradykinin, cholecystokinin,

30 label immunohistochemistry reveals that most gastrin-releasing peptide cells (approximately 70%) cont

31 Gastrin-releasing peptide-containing cells do not expres

32 reated with BBS, the amphibian equivalent of gastrin releasing peptide, demonstrated a similar MARCKS

33 Gastrin-releasing peptide fragment 14-27 and gastrin 17,

34 We previously reported that a gastrin-releasing peptide/gastrin-releasing peptide rece

35 We previously reported that a gastrin-releasing peptide/gastrin-releasing peptide rece

36 Gastrin, histamine, gastrin-releasing peptide, ghrelin, orexin, and glucocor

37 of 125I-labeled [Tyr4]BN to receptors for BN/gastrin releasing peptide (GRP) on Swiss 3T3 cells was d

38 taining either arginine vasopressin (AVP) or gastrin releasing peptide (GRP) were also compared betwe

39 nthesize GABA, CALB, VIP, calretinin (CALR), gastrin releasing peptide (GRP), and neurotensin (NT), a

40 Gastrin releasing-peptide (GRP) is a potent growth facto

41 483 cells with siRNA causes an inhibition of gastrin-releasing peptide (GRP) -induced phosphorylation

42 halocyanine-peptide conjugates targeting the gastrin-releasing peptide (GRP) and integrin receptors i

43 The G cell is activated by acetylcholine and gastrin-releasing peptide (GRP) and is inhibited by soma

44 Gastrin-releasing peptide (GRP) and its amphibian homolo

45 The gastrin-releasing peptide (GRP) and its receptor (GRPR)

46 for the oncogenic transformations induced by gastrin-releasing peptide (GRP) and its receptor, GRP-R,

47 of a cohort of itch-sensing genes, including gastrin-releasing peptide (GRP) and MAS-related GPCR mem

48 The mammalian bombesin peptides [gastrin-releasing peptide (GRP) and neuromedin B (NMB)]

49 NeuroD2 that contribute to these processes: gastrin-releasing peptide (GRP) and the small conductanc

50 Here we identify gastrin-releasing peptide (GRP) as a new angiogenic mole

51 We demonstrate that gastrin-releasing peptide (GRP) can inhibit the prolifer

52 Bombesin (BN) or gastrin-releasing peptide (GRP) can stimulate the growth

53 Gastrin-releasing peptide (GRP) causes multiple effects

54 only vasoactive intestinal polypeptide (VIP)/gastrin-releasing peptide (GRP) cells located ventrally

55 The bombesin/gastrin-releasing peptide (GRP) family of neuropeptides

56 ctions of spinal opioid-related peptides and gastrin-releasing peptide (GRP) in awake, behaving monke

57 ies showed that antagonists of bombesin (BN)/gastrin-releasing peptide (GRP) inhibit the growth of va

58 Brief light pulses or microinjection of gastrin-releasing peptide (GRP) into the third ventricle

59 Gastrin-releasing peptide (GRP) is a mitogen and morphog

60 Gastrin-releasing peptide (GRP) is a neuropeptide that a

61 Previous studies suggested that gastrin-releasing peptide (GRP) is an itch-specific neur

62 Gastrin-releasing peptide (GRP) is localized to the SCN

63 Gastrin-releasing peptide (GRP) is synthesized by pulmon

64 ed the effect of the number of receptors for gastrin-releasing peptide (GRP) on ligand affinity and o

65 The effects of antagonists of bombesin/gastrin-releasing peptide (GRP) on the growth of human m

66 ning the adult colon do not normally express gastrin-releasing peptide (GRP) or its receptor (GRPR).

67 plication of the bombesin-like neuropeptides gastrin-releasing peptide (GRP) or neuromedin B (NMB) pr

68 Overexpression of gastrin-releasing peptide (GRP) receptor (GRPR) in both

69 as cloned based on its homology to the human gastrin-releasing peptide (GRP) receptor and neuromedin

70 known human BLP receptor subtypes [i.e., the gastrin-releasing peptide (GRP) receptor, neuromedin B (

71 Gastrin-releasing peptide (GRP) receptors (GRPr) are fre

72 Gastrin-releasing peptide (GRP) receptors have been show

73 tides have demonstrated high affinity toward gastrin-releasing peptide (GRP) receptors in vivo that a

74 We have previously shown that gastrin-releasing peptide (GRP) stimulates neuroblastoma

75 amino acid peptide, is an analogue of human gastrin-releasing peptide (GRP) that binds to GRP recept

76 al for high affinity binding of bombesin and gastrin-releasing peptide (GRP) to the GRP-R.

77 Two probes for gastrin-releasing peptide (GRP), a known stimulatory ago

78 Gastrin-releasing peptide (GRP), a selective agonist for

79 , including the bombesin (BBS)-like peptide, gastrin-releasing peptide (GRP), and its cognate recepto

80 Although cyclooxygenase-2 (COX-2), gastrin-releasing peptide (GRP), and its receptor, GRP-R

81 epolarization and a second SCN neuropeptide, gastrin-releasing peptide (GRP), can acutely enhance and

82 hetamine-related transcript (CART), galanin, gastrin-releasing peptide (GRP), neuropeptide Y (NPY), n

83 Gastrin-releasing peptide (GRP), secreted by pulmonary n

84 oxide, vasoactive intestinal peptide (VIP), gastrin-releasing peptide (GRP), substance P, and calcit

85 a subset of spinal interneurons, labeled by gastrin-releasing peptide (Grp), that receive direct syn

86 Exemplified by gastrin-releasing peptide (GRP), these neuropeptides tra

87 Gastrin-releasing peptide (GRP), which is found within c

88 ied 5-HT1A as a key receptor in facilitating gastrin-releasing peptide (GRP)-dependent scratching beh

89 PAR-4 was also found on gastrin-releasing peptide (GRP)-positive neurons (pruric

90 s at 0.4 nM and was 30-fold more potent than gastrin-releasing peptide (GRP).

91 embrane domains of diphtheria toxin fused to gastrin-releasing peptide (GRP).

92 VIP), peptide histidine isoleucine (PHI) and gastrin-releasing peptide (GRP).

93 ry afferent-derived "itch" neurotransmitter, gastrin-releasing peptide (GRP).

94 ibutions from arginine vasopressin (AVP) and gastrin-releasing peptide (GRP).

95 A gastrin-releasing peptide (GRP)/GRP receptor-mediated au

96 ptor subtypes (neuromedin B [NMB]) receptor, gastrin-releasing peptide [GRP] receptor, and bombesin r

97 Normally, levels of mammalian bombesin (gastrin-releasing peptide [GRP]) drop postnatally, but t

98 e NMBR over the closely related receptor for gastrin-releasing peptide (GRPR), we used a chimeric rec

99 ry adenylate cyclase-activating peptide, and gastrin-releasing peptide have shown how these peptides

100 areas of the stomach, about one-third of all gastrin-releasing peptide immunoreactive (GRP-IR) neuron

101 al peptide-IR (VIP-IR), but not with that of gastrin-releasing peptide-IR (GRP-IR).

102 Furthermore, the findings suggest that gastrin-releasing peptide is a potential mediator of int

103 We found that gastrin-releasing peptide is specifically expressed in a

104 These neuropeptides, including gastrin-releasing peptide, neuromedin B, neurotensin, ga

105 e compounds demonstrated that antagonists of gastrin-releasing peptide/neuromedin B receptors (BB/BB)

106 ed by activation of cholinergic and bombesin/gastrin-releasing peptide neurons, acts mainly by releas

107 Bombesin, gastrin-releasing peptide, NMB, and a bombesin receptor

108 receptors: the neuromedin B-preferring, the gastrin-releasing peptide-preferring, and the bombesin-r

109 Pro-gastrin releasing peptide (pro-GRP) was identified as a

110 says are in high demand, and analysis of pro-gastrin releasing peptide (ProGRP) as a small cell lung

111 Bioconjugate affinity for the gastrin releasing peptide receptor (GRPR) as determined

112 The gastrin releasing peptide receptor (GRPr) has a high aff

113 into tumor cells, their affinity toward the gastrin releasing peptide receptor (GRPr), metabolic sta

114 e been proposed for diagnosis and therapy of gastrin releasing peptide receptor (GRPR)-expressing tum

115 lls transfected with the Gq-coupled bombesin/gastrin releasing peptide receptor, bombesin stimulated

116 Receptor-targeted agents, such as gastrin-releasing peptide receptor (BB2r)-targeted pepti

117 ed by cells expressing the G-protein-coupled gastrin-releasing peptide receptor (GRP-R) and is curren

118 The gastrin-releasing peptide receptor (GRP-R) is one of thr

119 imilar rationale, radioligands targeting the gastrin-releasing peptide receptor (GRP-R) might offer a

120 ll lines were made that stably expressed the gastrin-releasing peptide receptor (GRP-R) with receptor

121 receptors (neuromedin B receptor (NMB-R) and gastrin-releasing peptide receptor (GRP-R)).

122 s by the bombesin receptor family, including gastrin-releasing peptide receptor (GRP-R), neuromedin B

123 -coupled receptors currently consists of the gastrin-releasing peptide receptor (GRP-R), neuromedin B

124 udy we demonstrate that for the G(q)-coupled gastrin-releasing peptide receptor (GRP-R), phosphorylat

125 ceptor subtypes have been characterized: the gastrin-releasing peptide receptor (GRP-R), the neuromed

126 of G-protein-coupled receptors includes the gastrin-releasing peptide receptor (GRP-R), the neuromed

127 mutagenesis to address these issues with the gastrin-releasing peptide receptor (GRP-R).

128 al, G-protein coupled receptors includes the gastrin-releasing peptide receptor (GRP-R, or bb2), neur

129 However, the limited expression of gastrin-releasing peptide receptor (GRPR) and integrin a

130 We recently introduced the potent gastrin-releasing peptide receptor (GRPR) antagonist (68

131 e treatment of prostate cancer, radiolabeled gastrin-releasing peptide receptor (GRPr) antagonists ha

132 romosome occurred in the first intron of the gastrin-releasing peptide receptor (GRPR) gene and that

133 Because overexpression of the gastrin-releasing peptide receptor (GRPR) has been repor

134 MOR1D heterodimerizes with gastrin-releasing peptide receptor (GRPR) in the spinal

135 The overexpression of gastrin-releasing peptide receptor (GRPR) in various tum

136 Although our previous study suggested that gastrin-releasing peptide receptor (GRPR) is an itch-spe

137 The gastrin-releasing peptide receptor (GRPR) is found to be

138 Gastrin-releasing peptide receptor (GRPR) is overexpress

139 The gastrin-releasing peptide receptor (GRPr) is overexpress

140 The gastrin-releasing peptide receptor (GRPR) is overexpress

141 Gastrin-releasing peptide receptor (GRPr) is phosphoryla

142 A growing body of evidence suggests that gastrin-releasing peptide receptor (GRPR) might be a val

143 Ablation of gastrin-releasing peptide receptor (GRPR) or GRPR neuron

144 Here we describe that the gastrin-releasing peptide receptor (GRPR) plays an impor

145 In this study, we demonstrate that gastrin-releasing peptide receptor (GRPr) regulates ERK

146 he Trpv1-Cre population, depends on CGRP and gastrin-releasing peptide receptor (GRPR) transmission b

147 -expression of Shh and BBS-cognate receptor (gastrin-releasing peptide receptor (GRPR)).

148 Gastrin-releasing peptide receptor (GRPR), a member of t

149 BBN) is a peptide with high affinity for the gastrin-releasing peptide receptor (GRPr), a receptor th

150 tion of the mammalian bombesin (Bn) peptide, gastrin-releasing peptide receptor (GRPR), is an excepti

151 Its receptor, gastrin-releasing peptide receptor (GRPR), is expressed

152 Because expression of the gastrin-releasing peptide receptor (GRPR), somatostatin

153 peptide that binds with high affinity to the gastrin-releasing peptide receptor (GRPR), which is over

154 ptor (VIPR), substance P receptor (SPR), and gastrin-releasing peptide receptor (GRPR).

155 ic bombesin receptor antagonist that targets gastrin-releasing peptide receptor (GRPr).

156 g very high selectivity and affinity for the gastrin-releasing peptide receptor (GRPr).

157 The human gastrin-releasing peptide receptor (hGRP-R) is aberrantl

158 The murine gastrin-releasing peptide receptor (mGRP-R) is a member

159 c bacteriophage P1 clones encoding the mouse gastrin-releasing peptide receptor (mGRP-R).

160 is and to use bombesin analogs to target the gastrin-releasing peptide receptor for the diagnosis and

161 The bombesin (Bn)/gastrin-releasing peptide receptor GRP-R, which is coupl

162 kinase is dependent on the expression of the gastrin-releasing peptide receptor in rat 1A fibroblasts

163 icals, such as prostate-specific membrane or gastrin-releasing peptide receptor ligands for the imagi

164 FITC-labeled bombesin-like peptide with the gastrin-releasing peptide receptor on PC-3 and HT-29 cel

165 BON cells or BON cells stably expressing the gastrin-releasing peptide receptor treated with either p

166 between an agonist and an antagonist for the gastrin-releasing peptide receptor were found to have ex

167 ceptors (m3 muscarinic, V1a vasopressin, and gastrin-releasing peptide receptor) were coexpressed (in

168 3 and neuromedin-B receptor (NMB-R), but not gastrin-releasing peptide receptor.

169 ed independently of neurons that express the gastrin-releasing peptide receptor.

170 of patients, demonstrating the potential of gastrin-releasing-peptide receptor imaging.

171 Gastrin-releasing peptide receptors (GRP-R) are upregula

172 specificity of coupling interactions between gastrin-releasing peptide receptors (GRPrs) and their co

173 Gastrin-releasing peptide receptors (GRPrs) are overexpr

174 Gastrin-releasing peptide receptors (GRPRs) expressed on

175 ded to understand the expression of PSMA and gastrin-releasing peptide receptors in different types o

176 ic bombesin receptor antagonist that targets gastrin-releasing peptide receptors.

177 B, neurotensin, neuropeptide Y, peptide YY, gastrin-releasing peptide, somatostatin, and [Met5]enkep

178 expressing cells, but a second neuropeptide, gastrin-releasing peptide, still induced strong response

179 ase a number of peptides such as gastrin and gastrin-releasing peptide that could cause acid hypersec

180 ied two TMs (neuron-specific enolase and pro-gastrin-releasing peptide) that differentiate the risk o

181 cholecystokinin antagonists, carbachol, and gastrin-releasing peptide were monitored using video ima

182 Further, we demonstrate that gastrin-releasing peptide, which activates a Gq-coupled